EYE AND GLAUCOMA RESEARCH
Designation: Executive Director, R&D
Department: Ocular pharmacology
University: Santen Inc
Country: United States
Naj Sharif completed his graduation from Southampton University, England (UK), where he received his BSc (Joint Honors: Biochemistry and Physiology) and his PhD (Neuroscience). His pharmaceutical industry experience (>30 years) includes holding leadership positions in discovery research, drug development and regulatory affairs at Pfizer, Syntex (Roche), Alcon-Novartis. He is currently at Santen Inc. (Executive Director, R&D). His 23-tenure at Alcon resulted in his contributions to the discovery/development and US FDA approvals of Travatan®, Patanol®, Simbrinza®, and Pazeo® to treat glaucoma/ocular hypertension and ocular allergies. He is a Fellow of ARVO (FARVO), and of British Pharmacological Society (FBPhS). He received the inaugural Dr. Roger Vogel Award for ocular pharmaceutical research (2014), and the “Sir James Black Award” for contributions to drug discovery (2017). He serves on the editorial boards of numerous scientific journals and is an Adjunct Professor at several universities. He has published 200 scientific articles and edited 2 books, and is the holder of 23 issued patents.
- Ocular pharmacology
- Drug discovery & development
Open Access Journals
Subscribe to our Newsletter
Enter your e-mail address to stay informed about published articles, issue releases and latest updates on journal activities.
We openly welcome feedback and constructive criticism. Your compliments, concerns and suggestions regarding our services will prove enormously helpful in making them even better.
Do you have an idea or suggestion that can influence the Open Access community? Send an email to: email@example.com
Recently Released Issues
Copyright © 2020 Boffin Access Limited.